Tolvaptan in ADPKD Patients With Very Low Kidney Function
Open Access
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Kidney International Reports
- Vol. 6 (8) , 2171-2178
Abstract
No abstract availableKeywords
Funding Information
- Otsuka Pharmaceutical Development and Commercialization
This publication has 12 references indexed in Scilit:
- Autosomal dominant polycystic kidney diseaseThe Lancet, 2019
- Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2017
- Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney DiseaseAmerican Journal of Nephrology, 2017
- Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best PracticeNephrology Dialysis Transplantation, 2016
- Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney FunctionAmerican Journal of Kidney Diseases, 2015
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney diseaseKidney International, 2011
- A New Equation to Estimate Glomerular Filtration RateAnnals of Internal Medicine, 2009
- Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2008
- Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group.Journal of the American Society of Nephrology, 1995